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Abstract 
Background: Apelin is an endogenous ligand for the G protein-coupled receptor APJ. The association between 
apelin and cardiac modeling has been reported. However, if serum apelin affect the left ventricular hypertrophy (LVH) 
prevalence in hypertensive patients remains unknown.
Methods: We enrolled 344 untreated hypertensive patients. The presence of LVH was determined by echocardiog-
raphy. The blood was drawn from these patients and serum apelin level was detected. To study the direct effect of 
apelin on cardiac hypertrophy, cardiomyocytes were cultured and were transfected with apelin gene. Morphometric 
analysis and measurement of protein contain per cell were then performed.
Results: We observed a significantly lower serum apelin level in hypertensive patients with LVH compared with 
those without LVH. Receiver operating characteristic analyses shows that serum apelin level is robust in discrimi-
nating patients with LVH from those without. Our in vitro study showed that cellular protein content and cellular 
size was increased by Ang II treatment, which can be markedly inhibited by the apelin over-expression in cultured 
cardiomyocytes.
Conclusion: Our clinical date established a link between apelin and LVH, suggesting serum apelin may be used as a 
predicator for LVH prevalence in hypertensive patients. The direct evidence in vitro suggest apelin pathway is involved 
in the cardiomyocyte adaption to hypertrophic stimuli.
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Background
Left ventricular hypertrophy (LVH) is one of the major 
complications of hypertension [1, 2]. The prevalence of 
LVH is associated with significantly higher rate of cardio-
vascular disease, including angina pectoris, myocardial 
infarction, heart failure, cerebrovascular accidents, and 
sudden death [3]. Currently there is no reliable method to 
predict the prevalence of LVH in hypertensive patients. It 
is important to discover new markers which can identify 
patients prone to develop LVH.
Apelin is an endogenous ligand for the G protein-cou-
pled receptor APJ, which is synthesized as a 77-amino 
acid prepropeptide. Apelin/APJ system  exerts a variety 
of cardiovascular effects. A recent study shows that the 
cardiac apelin is markedly down-regulated in experi-
mental heart failure (HF) animal [4]. Apelin gene therapy 
increases myocardial vascular density and ameliorates 
diabetic cardiomyopathy via upregulation of sirtuin 3 
[5]. Apelin protects the brain against ischemia/reperfu-
sion injury through activating PI3K/Akt and ERK1/2 
signaling pathways [6]. Apelin also plays an important 
role in atherosclerosis development in mice [7]. Myo-
cardial injection of apelin-overexpressing bone marrow 
cells improves cardiac repair via upregulation of Sirt3 
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after myocardial infarction [8]. Apelin could reduce risk 
of contrast-induced nephropathy in patients with conges-
tive heart failure [9].
To date, apelin has been regard as a potential marker 
of coronary artery stenosis and atherosclerotic plaque 
stability in ACS patients and heart failure patients [10]. 
However, the association between the serum apelin and 
LVH in hypertensive patients remains unknown. In this 
study, we enrolled patients with essential hypertension 
(EH) and found that serum apelin is closely associated 
with the prevalence of LVH in these patients, suggesting 




A total of 344 patients newly diagnosed with EH were 
recruited in our hospital from April 2008 to September 
2013. All were untreated patients. Patients with second-
ary arterial hypertension, hypertrophic cardiomyopathy, 
valvular heart diseases, pulmonary hypertension, coro-
nary heart disease, liver/kidney insufficiency, metabolic 
disease, and immunological diseases were excluded from 
this study. According to the presence or absence of LVH, 
subjects were divided into LVH+ (patients with LVH) 
and LVH− (patients without LVH) groups. A complete 
medical history was obtained from all subjects, including 
diabetes mellitus (DM), alcohol intake, cigarette smok-
ing, weight, height, body mass index (BMI), systolic blood 
pressure (SBP), and diastolic blood pressure (DBP). BMI 
was calculated as following formula: BMI = Weight (kg)/
(Height (m)  ×  Height (m)) [11]. Biochemical variables 
including serum creatinine, total cholesterol (TC), total 
triglyceride (TG), high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C) 
were acquired from patient’s medical chart. The study pro-
tocol was approved by the ethics committee of our hospi-
tal. All patients provided an informed written consent.
Measurement of LVH
We measured left ventricular end-systolic dimen-
sion (LVESD), left ventricular end-diastolic dimension 
(LVEDD), end-diastolic interventricular septal (IVS) 
thickness, and left ventricle posterior wall thickness 
(PWT) using ultrasonic Doppler echocardiography (Acu-
son Sequoia 512, Siemens Medical Solutions, Mountain 
View, CA, USA). Three successive cardiac cycles were 
studied and left ventricle ejection fraction (LVEF, %) and 
fractional shortening (FS, %) were obtained based on the 
data. LV mass = 0.8 × 1.04 [(IVS + LVIDD + PWT)3 − 
LVIDD3] + 0.6. LVMI = LVM/height2.7. Left ventricular 
hypertrophy was defined as LVMI >49.2  g/m2.7 in men 
and LVMI >46.7 g/m2.7 in women.
Serum apelin, BNP and hs‑CRP level detection
The peripheral blood samples were collected from all 
participants after 12-h overnight fast. Apelin was meas-
ured by an ELISA kit (Apelin-12, Phoenix pharma-
ceuticals, Belmont, USA). The sensitivity was 0.05  ng/
mL, and intra- and inter-assay variations were <5 and 
<14  %, respectively. Serum high-sensitivity C-reactive 
protein (hs-CRP) measurements were performed using 
a commercially available high-sensitivity assay (Roche 
Diagnostics).
Rat neonatal cardiomyocytes culture and treatment
The whole hearts from neonate rats were isolated, 
minced and rinsed in hood by using by using the method 
invented and patented by Dr. Xuwei Hou (patent number: 
CN 101955884 A and CN 101955884 B). This method 
can protect cardiomyocyte from excessive enzyme dam-
age when being digested from cardiac tissue. Briefly, the 
whole hearts from neonate Wistar rats (age less than 
3 days) were isolated, minced and rinsed in hood. Five to 
six cycles of digestion using collagenase (95 U/ml) (Sigma 
Aldrich, Bornem, Belgium) and 0.6  U/ml of pancreatin 
(Sigma Aldrich, Bornem, Belgium) were performed. At 
the end of each cycle, the suspension was centrifuged and 
the supernatant collected, pooled, centrifuged and resus-
pended in the cardiac medium containing DMEM and 
M199 (volume ratio: 4:1) [12].
Apelin gene transfection
The apelin complementary DNA was purchased from Ori-
Gene (Rockville, MD, USA). The coding region was ampli-
fied with the following primers: 5′-CGCGAATTCGG 
CATGAATCTGCGGCTCTG and 5′-GCGCTCGAGTC 
AGAAAGGCATGGGTCC. The amplification products 
were subcloned into the pcDNA 3.1. vector using EcoRI 
and XhoI restriction enzymes (Invitrogen, Carlsbad, CA, 
USA). Cultured cardiomyocytes were transfected with a 
control or an apelin-encoding pcDNA 3.1 vector using 
the FuGENE 6 transfection reagent (Roche Diagnostic, 
Mannheim, Germany) according to the manufacturer’s 
guidelines. Stable transfectants were selected by their 
resistance to geneticin (400 µg/ml; GIBCO, Paisley, UK). 
After transfection, the cells were then treated with Ang 
II (500 nM) for 48 h to induce cellular hypertrophy [13].
Morphometric analysis
Forty-eight hours after Ang II (500  nM) treatment, cel-
lular hypertrophy was evaluated by measuring car-
diomyocyte cell surface using a digital image analysis 
system (Leica QwinV3, Leica Microsystems Ltd., Cam-
bridge, UK). To examine changes in cell morphology and 
cytoskeleton, cells were fixed in 4  %paraformaldehyde, 
stained with FITC-conjugated Phalloidin (Sigma) for 
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30 min and mounted in Vectashield with 4′,6-diamidino-
2-phenylindole (Vector Laboratories, Peterborough, UK). 
Cellular hypertrophy was evaluated by measuring cardio-
myocytes surfaces using a digital image analysis system 
(Leica QwinV3, Leica Microsystems Ltd., Cambridge, 
UK). Five random fields (with approximately 10–15 cells 
per field) from every sample were averaged and expressed 
as μm2/cell. All experiments were repeated three times.
Measurement of protein contain per cell
The cultured cardiomyocytes were trypsinized and counted 
using a cell counting chamber (Beckman Coulter, Fuller-
ton, CA, USA) and then lysed with RIPA buffer (Santa Cruz 
Biotechnology, Santa Cruz, USA). A total of 5 × 106 cells 
were used. The cell lysates were prepared to determine 
protein content by BCA protein assay kit (BioVision, Inc., 
Milpitas, CA, USA). Then the protein synthesis of cells was 
determined by dividing the total amount of protein by the 
number of cells, namely, protein per cell [14].
Western blotting analysis for cardiomyocyte hypertrophy 
markers
Collected cardiomyocytes were separated by trypsin and 
the protein concentration in the supernatant was deter-
mined with a BCA protein assay kit (Beyotime, Jiangsu, 
China). The isolated protein (25 μg) from cardiomyocytes 
was separated by 10 % SDS-PAGE and transferred onto 
polyvinylidene difluoride nylon membranes. The blots 
were probed with anti-rat Apelin peptide (1:1000 dilu-
tion, Santa Cruz Biotechnology, Santa Cruz, USA), anti-
rat atrial natriuretic peptide (ANP), Osteopontin (OPN) 
and transforming growth factor beta (TGF-β1) (all 1:1000 
dilution, Millipore, USA), anti-GAPDH antibody (1:1000 
dilution; Santa Cruz Biotechnology, Santa Cruz, USA). 
Then with horseradish peroxidase-conjugated secondary 
antibodies (1:5000 dilution), and visualized using an ECL 
detection kit (Amersham Biosciences, Piscataway, NJ, 
USA). The optical densities of the bands were quantified 
by densitometric analysis performed with a quantitative 
imaging system (Bio-Rad, USA). All western blot experi-
ments were repeated three times.
Statistical analysis
Data on quantitative characteristics are expressed as 
mean ± SD or mean. Data on qualitative characteristics 
are expressed as percent values or absolute numbers, as 
indicated. Differences in demographic characteristics 
and Analyses were performed using the software SPSS 
16.0 (SPSS Inc., Chicago, IL, USA). All P values were 
two-sided, and a P value <0.05 was considered signifi-
cant variables and the χ2 test for all categorical variables. 
Receiver operating characteristic (ROC) analyses was 
performed to determine a discriminative ability of apelin 
in LVH prevalence in these patients. We also performed 
a multivariate logistic regression with LVH+/LVH− as 
the dependent variable and serum apelin as a covariate 
adjusted at least for age, gender, BMI, diabetes, smok-
ing, SBP, and serum lipids (HDL- and LDL-cholesterol). 
The data of in  vitro experiments were compared with 
ANOVA analyses. Analyses were performed using the 
software SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All P 
values were two-sided, and a P value <0.05 was consid-
ered significant.
Results
Among all hypertensive patients, 98 were classified as 
hypertensive with LVH and 246 as hypertensive without 
LVH, according to the presence of LVH. There were no 
statistically significant differences between the two groups 
in age, sex, diastolic BP, TC, TG, LDL-C, and HDL-C 
(P  >  0.05;  Table  1). We found that LVH+ patients had 
higher percentage of smokers, higher BMI, systolic BP, 
serum hs-CRP levels than LVH- patients (both P < 0.05, 
Table  1). However, the serum apelin level was dramati-
cally lower in LVH+ patients (P  <  0.001). Pears correla-
tion analyses show a slight correlation between serum 
apelin and age and that there is no correlation between 
serum apelin and sex, BNP and hs-CRP (data not shown).
Using ROC curve and area under curve [15], we deter-
mined the sensitivity and specificity of apelin as a diag-
nostic marker of the prevalence of LVH in hypertensive 
patients. A ROC curve was created to estimate the serum 
APLN level with the highest sensitivity and specific-
ity. Figure 1 shows that serum apelin is able to discrimi-
nate LVH+ patients from the LVH− patients. Our ROC 
Table 1 The clinical and  biochemical characteristic of  all 
enrolled patients
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, 
TG total triglyceride, TC total cholesterol, HDL high-density lipoprotein 
cholesterol, LDL low-density lipoprotein cholesterol, SCR serum creatinine, 
Hs-CRP high sensitive-C-reactive protein
Variables LVH+ (139) LVH− (288) P value
Age (years) 54.4 ± 6.3 54.5 ± 9.1 0.861
Male (n, %) 85 (61.2 %) 171 (59.4 %) 0.404
Smoker (n, %) 42 (42.9 %) 70 (31.7 %) 0.001
BMI (kg/m2) 24.7 ± 2.5 24.3 ± 1.6 0.036
SBP(mmHg) 161.1 ± 12.4 152.2 ± 9.3 <0.001
DBP (mmHg) 84.2 ± 5.8 85.1 ± 5.7 0.111
TG (mmol/L) 1.7 ± 0.7 1.8 ± 0.6 0.069
TC (mmol/L) 5.0 ± 0.9 5.1 ± 0.9 0.394
HDL-C (mmol/L) 1.9 ± 0.7 1.8 ± 0.6 0.161
LDL-C(mmol/L) 3.0 ± 0.9 2.9 ± 1.0 0.401
sCr (mmol/L) 107.1 ± 31.3 105.3 ± 31.2 0.677
hs-CRP(mmol/L) 2.3 ± 0.8 1.7 ± 0.7 <0.001
Serum apelin (ng/mL) 1.7 ± .0.7 2.4 ± 0.7 <0.001
Page 4 of 7Ye et al. J Transl Med  (2015) 13:290 
analysis data revealed that serum apelin levels were 
robust in discriminating patients with LVH from those 
without, with an AUC value of 0.809 (95  % CI =  0.76–
0.85, P < 0.001). The overall best cut-off value for apelin 
protein was estimated as 1.92 ng/mL with 78 % specificity 
and 82 % sensitivity.
The multivariate logistic regression using LVH+/
LVH− as the dependent variable and serum apelin as a 
covariate adjusted for conventional risk factors listed in 
Table  1 show that the serum apelin is a protective fac-
tor against LVH prevalence (OR =  0.16, 95 % CI: 0.11–
0.25, P  <  0.001). Another factor associated with LVH 
was serum hs-CRP level (OR  =  3.1, 95  % CI: 2.1–4.5, 
P  <  0.001). Other factor, such as age, gender, BMI, dia-
betes, smoking, SBP, and serum lipids (HDL- and LDL-
cholesterol, were not associated with LVH prevalence.
We next detected apelin protein expression in cultured 
cardiomyocytes receiving apelin gene and control trans-
fection. Western blot assay showed that the apelin gene 
transfection dramatically increased the apelin level com-
pared to control cells (Fig. 2).
Our in vitro study showed that the cellular protein con-
tent and surfaces were similar between cardiomyocyte 
over-expressing apelin and control cells in the absence of 
Ang II treatment. However, when cells were treated with 
Ang II, control cells without apelin over-expression had 
significantly increased in cellular protein content and 
surfaces. In contrast, the cellular protein content and sur-
faces in apelin over-expressing cardiomyocytes did not 
increase markedly (Fig. 3a, b).
Figure 4 shows Ang II treatment induced dramatically 
increases of the several cardiac hypertrophy markers, 
such as OPN, ANP, and TGF-β in cardiomyocytes. As we 
expected, we observed that the apelin over-expression 
abolished the Ang II induced increases in these hypertro-
phy marker expressions in cardiomyocytes (Fig. 4).
Discussion
The present study demonstrated significantly lower 
serum apelin level in hypertensive patients with echocar-
diographic evidence of LVH compared with hypertensive 
patients without LVH. It also showed an independent 
association of low apelin level with LVH prevalence after 
adjusting for other confounding clinical parameters.
LVH is considered to be a critical intermediate phe-
notype in the progression of hypotensive heart disease 
and is related to adverse outcomes [16]. Pathological 
changes in patients with hypertensive LVH consist of 
increased size of the cardiomyocyte, and altered extracel-
lular matrix with accumulation of fibrosis [17]. There is 
considerable interindividual variability observed in the 
development and pattern of LVH [18, 19]. While exten-
sive efforts have been made to identify putative genetic 
risk factors that could modulate LVH, including candi-
date gene association studies and genome-wide asso-
ciation studies [20, 21], these have yet to yield clinically 
applicable results.
The involvement of the apelin–APJ system in hyperten-
sion has been studied extensively in the past few years [22, 
23], nevertheless, in the setting of hypertensive patients 
with LVH, there is little knowledge about the role of ape-
lin. Przewlocka-Kosmala et  al. have documented lower 
apelin levels in hypertensive patients with more severe left 
ventricular systolic and diastolic function abnormalities 
than their peers with higher apelin levels [24]. Notably, 
those patients had used antihypertensive drugs before the 
Fig. 1 The ROC curve of serum apelin level. Serum apelin at 1.92 ng/
mL is excellent to discriminate LVH prevalence in hypertensive 
patients, with 78 specificity and 82 % sensitivity. The AUC value was 
0.809 (95 % CI = 0.76 to −0.85, P < 0.001)
Fig. 2 The apelin protein detection in cultured cardiomyocytes 
after apelin gene and control transfection by Western blot assay. Our 
results showed that the gene transfection caused a markedly increase 
in the apelin level compared to control cells
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study; therefore, the influence of pharmacotherapy on the 
results cannot be entirely ruled out.
In line with the observation mentioned above, the 
result presented here showed that low serum apelin lev-
els were associated with LVH prevalence in untreated 
hypertensive patients. Additionally, the association 
between serum apelin and LVH prevalence in several 
multivariate models remained statistically significant 
after adjustments for the major commonly recognized 
risk factors, including BMI, systolic blood pressure 
and serum hs-CRP. Furthermore, we used neonatal rat 
cardiomyocytes to directly test the effects of apelin on 
cardiac hypertrophy induced by AngII. In accordance 
with our clinical data, in  vitro results demonstrated 
that overexpression of apelin could attenuate the AngII-
mediated increase in cell size, protein content and the 
expression of pro-hypertrophic and/or pro-fibrotic fac-
tors, including TGF-b, OPN and ANP [25–27]. These 
findings are also consistent with previous findings 
showing that Apelin-APJ signaling could counteract the 
effects of AngII. For instance, administration of apelin 
blocks a spectrum of AngII-mediated effects on athero-
sclerosis in the apolipoprotein E-deficient mice through 
the formation of a heterodimer between the apelin and 
AngII receptors [7]. Apelin also protects wild type mice 
against AngII-induced hypertension and cardiovascular 
fibrosis via direct regulation of PAI-1 gene expression 
[28].
A substantial body of evidence supports the concept 
that apelin could prevent cardiovascular remodeling 
induced by myocardial infarction or by pressure overload 
in mice or rats through different mechanisms [12, 25, 
29–33]. In addition, it has previously been suggested that 
apelin causes vasodilation in animal models as well as in 
clinical studies [34, 35]. Moreover, experimental evidence 
indicates that apelin is among the most potent endoge-
nous inotropic agents [22]. Apelin induces angiogenesis 
in post-myocardial infarction of diabetes [36]. Apelin 
gene therapy increases myocardial vascular density and 
ameliorates diabetic cardiomyopathy via upregulation of 
sirtuin [5].
Several limitations should be addressed in this study. 
Firstly, a larger scale study with serial assessment of 
ventricular structure and function would be desirable. 
Secondly, this study was a cross-sectional study, not a 
longitudinal study. A follow-up is needed to evaluate the 
relation between apelin and LVH incidence and regres-
sion. Thirdly, it would be interesting for future studies to 
demonstrate the association between all forms of apelin 
and LVH.
Conclusion
In conclusion, we have reported that serum apelin level 
is strongly and independently related to LVH in a popu-
lation with essential hypertension, suggesting that this 
peptide may be used as a biomarker of LVH. In addition, 
considering apelin’s vasodilating and inotropic proper-
ties, the apelin system may lead to the development of 
Fig. 3 The hypertrophic changes of cultured cardiomyocytes over-
expression apelin and controls. The hypertrophic changes of cells 
were indicated by the cellular protein content and cellular surfaces 
sizes. a Cultured cardiomyocytes had similar cellular protein contents 
between control and apelin gene transfection cells. However, when 
treated with Ang II, the cells over-expressing apelin had significantly 
lower protein contents. b The typical images of cellular size before 
and after Ang II treatment in cultured cardiomyocytes over-expres-
sion apelin and controls. Cardiomyocytes had similar cellular sizes 
between control and apelin gene transfected cells. After Ang II treat-
ment, the cells over-expressing apelin had significantly smaller size 
than controls
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new therapeutic regimens, both for lowering blood pres-
sure and improving myocardial performance.
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